Status:
WITHDRAWN
Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy
Lead Sponsor:
Asociación para Evitar la Ceguera en México
Conditions:
Central Serous Chorioretinopathy
Eligibility:
All Genders
20-50 years
Phase:
PHASE2
PHASE3
Brief Summary
Central serous chorioretinopathy (CSC) has been known since it was first described by Von Graefe and termed "idiopathic detachment of the macula" in 1866, is a well-characterized disorder leading to s...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Any visual acuity.
- Central serous chorioretinopathy
Exclusion
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00418431
Start Date
April 1 2006
End Date
August 1 2006
Last Update
June 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asociacion para Evitar la Ceguera en Mexico
Mexico City, Mexico City, Mexico, 04030